Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database

As ibrutinib has become a standard of care in B-cell malignancies in monotherapy or in combination with other agents, definition of its safety profile appears essential. The aim of this study was to further characterize the safety profile of ibrutinib through the identification of potential safety s...

Full description

Bibliographic Details
Main Authors:	Marion Allouchery, Cécile Tomowiak, Thomas Lombard, Marie-Christine Pérault-Pochat, Francesco Salvo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Pharmacology
Subjects:	ibrutinib Bruton’s tyrosine kinase inhibitor drug safety adverse drug reaction pharmacovigilance
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.769315/full

Similar Items

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
by: Peter Hillmen, et al.
Published: (2021-05-01)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
by: Alexander P. de Porto, et al.
Published: (2019-01-01)

Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
by: Katarzyna Szklener, et al.
Published: (2022-04-01)

Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
by: Julian Matthias Metzler, et al.
Published: (2020-12-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias
by: Yilin Pan, et al.
Published: (2024-11-01)

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome
by: Yuehua Huang, et al.
Published: (2022-04-01)

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
by: Ana-Maria Moldovianu, et al.
Published: (2023-02-01)

Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment
by: Bernhard Schlevogt, et al.
Published: (2019-08-01)

Impact of ibrutinib on inflammation in a mouse model of Graves’ orbitopathy
by: Charm Kim, et al.
Published: (2024-08-01)

Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
by: Saadia Sherazi, et al.
Published: (2023-03-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Waldenström macroglobulinemia: biology, genetics, and therapy
by: Paludo J, et al.
Published: (2016-07-01)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
by: Susan M. O’Brien, et al.
Published: (2021-11-01)

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases
by: Yu. S. Torshina, et al.
Published: (2023-06-01)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
by: Gaurav Nepal, et al.
Published: (2022-01-01)

Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib—findings from three cases
by: Marion Blaize, et al.
Published: (2024-05-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
by: Chao Xue, et al.
Published: (2020-09-01)

Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma
by: Jun Du, et al.
Published: (2024-07-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023-01-01)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
by: Mickaël Martin, et al.
Published: (2020-10-01)

Pharmacovigilance: Scope for a dermatologist
by: Bhanu Prakash, et al.
Published: (2011-01-01)

Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations
by: Xiangfan Yu, et al.
Published: (2022-11-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

A Case of Hypophosphatemiawith Increased Urinary Excretion of Phosphorus Associated with Ibrutinib
by: Ewa M. Wysokinska, et al.
Published: (2016-04-01)

Ibrutinib-associated osteonecrosis of the jaw
by: Annu Singh, et al.
Published: (2024-03-01)

Pharmacovigilance: Empowering healthcare professionals
by: Mugoša Snežana S., et al.
Published: (2015-01-01)

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
by: Michele Fusaroli, et al.
Published: (2024-11-01)

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
by: Jing Shen, et al.
Published: (2022-11-01)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
by: Brooke Benner, et al.
Published: (2021-01-01)

Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia
by: Helbies Bedier, et al.
Published: (2021-01-01)

Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients
by: Alan O. Vázquez-Alvarez, et al.
Published: (2017-12-01)

Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective
by: Yekta Ghane, et al.
Published: (2023-12-01)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
by: Ridhima Kapoor, MD, et al.
Published: (2021-11-01)